Pair of Roche deals add allogeneic cell therapies, first-in-class fibrosis molecule

Roche spent more than $200 million in upfront payments to expand its interest in allogeneic cell therapies for cancer and add a first-in-class molecule for fibrosis.

On Wednesday, Poseida Therapeutics Inc. (NASDAQ:PSTX) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive rights and options to multiple allogeneic CAR T therapy programs, including P-BCMA-ALLO1, which is a BCMA-targeted CAR T therapy in Phase I testing to treat multiple myeloma; and P-CD19CD20-ALLO1, a dual-targeting CAR T against CD19 and CD20 that is expected to enter the clinic next year. The partners will also jointly discover and develop next-generation allogeneic CAR T therapies that Roche would have an option to license...